Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

L.A. McKeown

March 29, 2025

News Daily News

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Yael L. Maxwell

February 27, 2025

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

L.A. McKeown

October 25, 2024

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Caitlin E. Cox

March 24, 2021

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

Lucy Hicks

February 15, 2019

News Daily News

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

Michael O'Riordan

April 20, 2018

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

Advertisement

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

October 2024 Dispatch for the CV Team

October 2023 News Roundup

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

CV Care Around Noncardiac Surgery: New ESC Guidelines

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

More Evidence Links Breast Arterial Calcification and CVD Risk

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

The Higher the LDL, the Bigger the Mortality Benefit of Intensive Therapy: Meta-analysis

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Symic Biomedical Selects Vascular Clinical Candidate

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content